Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab pegol observational cohort in rheumatoid arthritis with lipid profile monitoring
NL-OMON36770Recruiting
- Sponsor
- Reade
- Start
- Mar 2011
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label, single-arm trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by Reade. Primary endpoints: Efficacy of certolizumab pegol over 48 months and Safety of certolizumab pegol over 48 months. Started Mar 2011; status: recruiting.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON36770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36770.